https://www.biotechdaily.com.au/index.php

Biotech Daily Home

Biotech Daily covers the major announcements from more than 140 ASX-listed biotech companies as well as the major research institutes and developments in government policy.

Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector.

The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter.

Base-rate subscriptions are $A1500 a year (including GST in Australia).

Subscribers include biotech directors and CEOs, major pharmaceutical companies, universities, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.

 

Download subscription form here
 

 

 

Latest News !
 

Cyclopharm: US Technegas Trial Meets Endpoints Early

Opyl: A I Predicts Trial Results - Including Covid-19

Biotech Daily 1st Medical Marijuana Survey

CSIRO, Doherty Distance From 'Tier 1' Sars-Cov-2 Claims

Biotech Daily Editorial: Covid-19 Spruikers, Please Stop !

Dr Boreham's Crucible: Proteomics International Laboratories

Zelira: Marijuana ZLT-101 'Effective For Insomnia'

FDA Clears Mesoblast Remestemcel-L For Covid-19 ARDS

Biotech Daily Editorial: Covid-19 Coronavirus Claims

Dr Boreham's Crucible Special: Covid-19

Biotech Daily Editorial: 2019-nCoV Coronavirus (Covid-19)

 All The Dope On Medicine, Marijuana, Cannabis & Hemp 

 


 August BDI-40 Up 8%, ASX200 2%; Big Caps Down 0.2%

Kazia Up 96%, Prescient 68%, Dimerix 66%
Osprey Down 30%, LBT 16%

 

September 1, 2020

 
By comparison, the benchmark ASX200 was up 2.2 percent in August to 6,061 points, still 8.2 percent below August 31, 2019. The BDI-40 was up 12.9 percent for the year to August 31, 2020. The Nasdaq Biotechnology Index was up 0.9 percent in August and 31.7 percent for the year.
 
The three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) slipped 0.2 percent in August, but were up 19.5 percent for the year.
 
Most of the Big Caps loss was due to Resmed falling 13.4 percent to $35,022 million, despite posting revenue up 13.4 percent and net profit after tax up 31.6 percent to $962 million. Cochlear slipped half a percent to $12,631 million, while CSL climbed 4.3 percent to $129,960 million.
 
For the month of August, 23 of the BDI-40 companies were up, 17 by more than 10 percent and 11 by more than 20 percent. Seventeen fell, with six down by more than 10 percent.
 
Mesoblast was the largest contributor to the BDI-40 gains, up $869 million following a successful US Food and Drug Administration committee hearing.
 
But the biggest percentage gain went to Kazia up 96.2 percent to $104 million on the FDA August hat-trick of rare paediatric disease approval, fast-track designation and orphan drug designation for paxalisib, formerly known as GDC-0084, for brain cancers - proving that chief executive officer Dr James Garner, unlike his Hollywood namesake, is no (Bret) maverick.

Prescient was up $15 million or 68.2 percent to $37 million, followed by Dimerix (65.9%), Alterity (48.7%), Cynata (42.5%), Mesoblast (38.8%), Starpharma (37.6%), Optiscan (36.4%), Orthocell (28.1%), Telix (27.0%), Universal Biosensors (22.2%), Antisense (15.8%), Avita (15.6%), Amplia (15.4%), Pharmaxis (15.15%), and Actinogen (11.5%).
 
Osprey led the falls, down 30 percent to $42 million, followed by LBT Innovations (16.3%), Uscom (13.3%), Compumedics (11.5%), Paradigm (10.8%), Resonance (10.1%) and Impedimed (9.0%).
 
The 22 companies that comprise Cannabis Corner were ip 7.5 percent in August to $1,146 million, but down 40.9 percent for the year, from the all-time high of $1,939 million.
 
On the Nasdaq, Queensland’s Protagonist jumped 42.2 percent to $1,118 million, Redhill (with Australian assets) was up 0.8 percent to $395 million, with Eyepoint (Psivida) down 26.6 percent to $91 million.
 
 
 
BDI-40 v S&P ASX200 Jun 30, 2006 to Aug 31, 2020 
 
 
5-Year Big Caps (Cochlear, CSL, Resmed) to Aug 31, 2020


BDI-40 ($m) v S&P ASX200 – Year to Aug 31, 2020 
(current, raw data)
 

  

 

 Click here for Biotech Daily's archive

 

   

Biotech Daily Top 40 With Market Capitalization At August 31, 2020

 

* Biotech Daily editor, David Langsam, owns shares in Acrux, Alcidion, Alterity, Amplia, BTC Health, Cochlear
   Cynata, Mesoblast, Nanosonics, Neuren, Patrys, Polynovo, Telix and Volpara, as well as non-biotechnology stocks.
   Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies. 

   These holdings are liable to change: 
   https://www.australianethical.com.au/personal/ethical-investing/companies-we-invest-in/